This set of documents contains supporting information for use in submitting a dermatological product for consideration by the Advisory Committee for Borderline Substances (ACBS).
- the mechanism for ensuring patient safety
- products that will not be considered
- clinical trial information be applied for type 1 products
The documents can be used when filling out the
dermatological products application form.